Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2020 | QOL in MONALEESA-2, 3, and 7

Aditya Bardia • 22 Sep 2020
ESMO 2020
Breast Cancer Fulvestrant Ribociclib
MONALEESA-2 MONALEESA-3 MONALEESA-7

Aditya Bardia, MD, MPH, Massachusetts General Hospital, Boston, MA, reports the quality of life (QOL) in three trials; MONALEESA-2, 3, and 7. The MONALEESA-2 trial (NCT01958021) investigated the efficacy of the ribociclib (LEE01) in postmenopausal women with hormone receptor-positive (HR+), HER2 negative (HER2–) advanced breast cancer (ABC). The MONALEESA-3 trial (NCT02422615) investigated the use of ribociclib plus fulvestrant in postmenopausal women and men with HR+, HER2– ABC who have received no or one line of endocrine therapy. Finally, the MONALEESA-7 trial (NCT02278120) investigated the use of ribociclib in premenopausal women and HR+/HER2− ABC. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Aditya Bardia

lidERA trial: giredestrant improves invasive disease-free survival in ER+/HER2- early breast cancer
3:01
lidERA trial: giredestrant improves invasive disease-free survival in ER+/HER2- early breast cancer
Aditya Bardia • 10 Dec 2025
Updated results by duration of prior CDK4/6i in the met setting of the Phase III EMERALD trial
2:21
Updated results by duration of prior CDK4/6i in the met setting of the Phase III EMERALD trial
Aditya Bardia • 7 Dec 2022
TALENT: neoadjuvant T-DXd with or without anastrozole for HER2-low, HR+ early stage breast cancer
2:59
TALENT: neoadjuvant T-DXd with or without anastrozole for HER2-low, HR+ early stage breast cancer
Aditya Bardia • 7 Dec 2022
AMEERA-5: amcenestrant + palbociclib for previously untreated ER+/HER2- advanced breast cancer
1:25
AMEERA-5: amcenestrant + palbociclib for previously untreated ER+/HER2- advanced breast cancer
Aditya Bardia • 8 Dec 2021

Related Videos

How will SARMs fit into the current breast cancer treatment paradigm?
1:14
How will SARMs fit into the current breast cancer treatment paradigm?
Rafael Grochot • 2 Jul 2026
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
1:35
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
Rafael Grochot • 2 Jul 2026
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
1:07
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
Sanjoy Chatterjee • 17 May 2026
Design and aim of the HYPORT study in regional nodal breast cancer
1:23
Design and aim of the HYPORT study in regional nodal breast cancer
Sanjoy Chatterjee • 17 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals